The optimal dose depends on individual tolerance and the specific weight-loss goal being pursued
Injection-Based Administration Subcutaneous injections: All GLP-1 RAs are administered via subcutaneous injection Prefilled pens: Most common delivery system, allows for self-administration Auto-injectors: Simplify the process for patients with dexterity issues Multi-dose pens: Require dose dialing and needle attachment Dosing frequency: Daily: Liraglutide (Saxenda, Victoza), some formulations of exenatide (Byetta) Weekly: Semaglutide (Wegovy, Ozempic), tirzepatide (Mounjaro, Zepbound), dulaglutide (Trulicity), exenatide extended-release (Bydureon) Titration schedules: Most FDA-approved GLP-1 RAs require gradual dose escalation to minimize gastrointestinal side effects
GHK-Cu is primarily studied for skin regeneration, wound healing, collagen stimulation, anti-inflammatory signaling, antioxidant defense, hair follicle health, and broad gene expression modulation
Treatment with LDN shows promise for patients with persistent pain symptoms, including fibromyalgia and Ehlers-Danlos syndrome (EDS)
Secretagogues stimulate GH release via ghrelin or GHRH receptors
